FAQ

BNP 1350

Known as: BNP-1350, BNP1350, DB 172 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2016
01220002016

Related topics

Related topics

1 relation

Broader (1)

cositecan

Related mentions per year

Related mentions per year

1999-2016
1990200020102020
BNP 1350
cositecan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Karenitecin (bnp1350) and flavopridol as radiosensitizers in malignant glioma.
The poor prognosis of malignant glioma patients highlights the need to develop low toxicity, tumor specific agents with the… (More)
Is this relevant?
2009
2009
Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
Organic anion-transporting polypeptides (OATPs) are important uptake transporters that can have a profound impact on the systemic… (More)
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2005
2005
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
PURPOSE A phase II trial of the novel camptothecin karenitecin (BNP1350) was conducted to determine its efficacy and tolerability… (More)
  • table 2
  • table 3
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2004
2004
Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates
BNP1350 (7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin, karenitecin), a highly lipophilic camptothecin, a high percentage of… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2002
2002
Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350.
A novel karenitecin, BNP1350, is a topoisomerase I-targeting anticancer agent with significant antitumor activity in vitro and in… (More)
Is this relevant?
2002
2002
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
The novel camptothecin derivative BNP1350 (7-[2-trimethylsilyl)ethyl]-20(S)-camptothecin), also known as Karenitecin, has been… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2001
2001
The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer
Promotion of apoptosis may potentiate the sensitivity of tumor cells to chemotherapeutic agents, thus improving the efficacy of… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 6
Is this relevant?
2000
2000
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
BNP1350, 7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin, is a novel semi-synthetic, highly lipophilic, silicon-containing… (More)
Is this relevant?
2000
2000
Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
Cellular topoisomerase I is an important target in cancer chemotherapy. A novel karenitecin, BNP1350, is a topoisomerase I… (More)
  • figure 2
  • figure 3
  • figure 5
  • figure 6
  • figure 7
Is this relevant?